Alzheimer’s disease is the most common form of dementia, accounting for up to 80% of dementia cases. It is a progressive, degenerative neurological disorder that causes memory loss and other impairments in cognitive function. It is estimated that 5.7 million Americans currently live with Alzheimer's, and the vast majority are over the age of 65. Alzheimer’s is characterized by a buildup of abnormal proteins in the brain (known as amyloid plaques and neurofibrillary tangles) that damage neurons and eventually cause them to deteriorate and die. Other cognitive changes like language and visuospatial deficits, as well as problems with executive functions, like problem solving and planning, are also common. In addition to Alzheimer’s, there are several other types of dementia that can cause memory loss and other cognitive impairments. Vascular dementia, which is caused by damage or blockages in the blood vessels that supply the brain, is the second most common type of dementia after Alzheimer’s. Symptoms include changes in memory, behavior, and language, as well as difficulty with problem solving and executive functions. Other causes of dementia include Lewy body dementia, frontotemporal dementia, and traumatic brain injury. Prevention of Alzheimer’s and other types of dementia is not yet possible, as the exact cause of the disease is still unknown. However, researchers are focusing on ways to mitigate the risk factors associated with Alzheimer’s. These include living a healthy lifestyle, engaging in social activities, engaging in physical and cognitive activities, and controlling high blood pressure and cholesterol levels. Additionally, research is also focusing on potential treatments, such as drugs and interventions aimed at reducing damaged nerve cells and restoring lost memories.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom